Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 7
HOS-148868 · Präparat HOS-099980
The overall safety profile for the booster dose was similar to that seen after the primary course. The
most frequent adverse reactions in children 5 to 11 years of age after the booster dose were injection
site pain (> 60%), fatigue (> 30%), headache (> 20%), myalgia, chills, injection site redness and
swelling (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 15f69db96e29e9e733485fc344dca5a768ab48697b617adccfead5f0f7502bbc · Zeichen 2463–2784 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 7
HOS-148869 · Präparat HOS-099980
Adolescents 12 to 15 years of age – after 2 doses
In an analysis of long-term safety follow-up in Study 2, 2 260 adolescents (1 131 Comirnaty and
1 129 placebo) were 12 to 15 years of age. Of these, 1 559 adolescents (786 Comirnaty and
773 placebo) have been followed for ≥ 4 months after the second dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 6f9870b1951df5df75fece494be4abb350196e5b8ee5362d960ae784f81d4d79 · Zeichen 2786–3091 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 7–8
HOS-148870 · Präparat HOS-099980
7
The overall safety profile of Comirnaty in adolescents 12 to 15 years of age was similar to that seen in
participants 16 years of age and older. The most frequent adverse reactions in adolescents 12 to
15 years of age that received 2 doses were injection site pain (> 90%), fatigue and headache (> 70%),
myalgia and chills (> 40%), arthralgia and pyrexia (> 20%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 6e641667c3d63906b968ff34b5b180d74db743fd7df8252eccf1f6f504be412f · Zeichen 3145–3511 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148871 · Präparat HOS-099980
Participants 16 years of age and older – after 2 doses
In Study 2, a total of 22 026 participants 16 years of age or older received at least 1 dose of the
initially approved Comirnaty vaccine and a total of 22 021 participants 16 years of age or older
received placebo (including 138 and 145 adolescents 16 and 17 years of age in the vaccine and
placebo groups, respectively). A total of 20 519 participants 16 years of age or older received 2 doses
of Comirnaty.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage eb477efe08056c71882b291450a8e1fd2a9d8af8bd287f77c91ed94bc7b0f6c3 · Zeichen 3513–3976 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148872 · Präparat HOS-099980
At the time of the analysis of Study 2 with a data cut-off of 13 March 2021 for the placebo-controlled
blinded follow-up period up to the participants’ unblinding dates, a total of 25 651 (58.2%)
participants (13 031 Comirnaty and 12 620 placebo) 16 years of age and older were followed up for
≥ 4 months after the second dose. This included a total of 15 111 (7 704 Comirnaty and 7 407 placebo)
participants 16 to 55 years of age and a total of 10 540 (5 327 Comirnaty and 5 213 placebo)
participants 56 years of age and older.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage d670c7377786468a76d88b5aa8874f640a095f2ea8cabc705f9b9cf4bf9a36f9 · Zeichen 3978–4506 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148873 · Präparat HOS-099980
The most frequent adverse reactions in participants 16 years of age and older that received 2 doses
were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 40%), chills
(> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or
moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of
reactogenicity events was associated with greater age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 2cb17403bcd52f73632234cbdca0828400980a25d336a4e71b3b047244f05c7e · Zeichen 4508–4955 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148874 · Präparat HOS-099980
The safety profile in 545 participants 16 years of age and older receiving Comirnaty, that were
seropositive for SARS-CoV-2 at baseline, was similar to that seen in the general population.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage ff63aadd10718c5f599c983e646be703cb47b611f000fba58bf87ff4503c332f · Zeichen 4957–5145 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148875 · Präparat HOS-099980
Participants 12 years of age and older – after booster dose
A subset from Study 2 Phase 2/3 participants of 306 adults 18 to 55 years of age who completed the
original Comirnaty 2-dose course, received a booster dose of Comirnaty approximately 6 months
(range of 4.8 to 8.0 months) after receiving Dose 2. Overall, participants who received a booster dose,
had a median follow-up time of 8.3 months (range 1.1 to 8.5 months) and 301 participants had been
followed for ≥ 6 months after the booster dose to the cut-off date (22 November 2021).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 445ff7c313352699daa23fc4f2d061ba75695353f8d20915a07db3c624581a8c · Zeichen 5147–5688 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148876 · Präparat HOS-099980
The overall safety profile for the booster dose was similar to that seen after 2 doses. The most frequent
adverse reactions in participants 18 to 55 years of age were injection site pain (> 80%),
fatigue (> 60%), headache (> 40%), myalgia (> 30%), chills and arthralgia (> 20%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage f50c78fbf1ff403a15f3c9eab7e3489b1e3e02a2b766288ce2d860f44c4443c0 · Zeichen 5690–5968 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148877 · Präparat HOS-099980
In Study 4, a placebo-controlled booster study, participants 16 years of age and older recruited from
Study 2 received a booster dose of Comirnaty (5 081 participants), or placebo (5 044 participants) at
least 6 months after the second dose of Comirnaty. Overall, participants who received a booster dose,
had a median follow-up time of 2.8 months (range 0.3 to 7.5 months) after the booster dose in the
blinded placebo-controlled follow-up period to the cut-off date (8 February 2022). Of these,
1 281 participants (895 Comirnaty and 386 placebo) have been followed for ≥ 4 months after the
booster dose of Comirnaty. No new adverse reactions of Comirnaty were identified.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage d1e0d0f27a5eac52ae8c47222c7b689773a53a0e809a09b4cc9e38a69a68265c · Zeichen 5970–6643 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148878 · Präparat HOS-099980
A subset from Study 2 Phase 2/3 participants of 825 adolescents 12 to 15 years of age who completed
the original Comirnaty 2-dose course, received a booster dose of Comirnaty approximately
11.2 months (range of 6.3 to 20.1 months) after receiving Dose 2. Overall, participants who received a
booster dose, had a median follow-up time of 9.5 months (range 1.5 to 10.7 months) based on data up
to the cut-off date (3 November 2022). No new adverse reactions of Comirnaty were identified.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 1803bcea6241e39da116a39b8a495b5ddb2f53fd524ade4079cdb25c5ed46324 · Zeichen 6645–7130 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8
HOS-148879 · Präparat HOS-099980
Participants 12 years of age and older – after subsequent booster doses
The safety of a booster dose of Comirnaty in participants 12 years of age and older is inferred from
safety data from studies of a booster dose of Comirnaty in participants 18 years of age and older.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 38317c9ed64c3bf5da630502c04cc15d413e04d44991e5a8e29af11d504374d5 · Zeichen 7132–7403 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 8–9
HOS-148880 · Präparat HOS-099980
8
A subset of 325 adults 18 to ≤ 55 years of age who had completed 3 doses of Comirnaty, received a
booster (fourth dose) of Comirnaty 90 to 180 days after receiving Dose 3. Participants who received a
booster (fourth dose) of Comirnaty had a median follow-up time of 1.4 months up to a data cut-off
date of 11 March 2022. The most frequent adverse reactions in these participants were injection site
pain (> 70%), fatigue (> 60%), headache (> 40%), myalgia and chills (> 20%), and arthralgia (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 7ffb952676c40362f874c3480909121e231c1b09207091a80d1af0a8f93f968e · Zeichen 7457–7959 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148881 · Präparat HOS-099980
In a subset from Study 4 (Phase 3), 305 adults > 55 years of age who had completed 3 doses of
Comirnaty, received a booster (fourth dose) of Comirnaty 5 to 12 months after receiving Dose 3.
Participants who received a booster (fourth dose) of Comirnaty had a median follow-up time of at least
1.7 months up to a data cut-off date of 16 May 2022. The overall safety profile for the Comirnaty
booster (fourth dose) was similar to that seen after the Comirnaty booster (third dose). The most
frequent adverse reactions in participants > 55 years of age were injection site pain (> 60%),
fatigue (> 40%), headache (> 20%), myalgia and chills (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 80ee242c31de85c6f4c48fe4228c02b93b238ada26636e7aa1a8e36976ddac8e · Zeichen 7961–8607 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148882 · Präparat HOS-099980
Booster dose following primary vaccination with another authorised COVID-19 vaccine
In 5 independent studies on the use of a Comirnaty booster dose in individuals who had completed
primary vaccination with another authorised COVID-19 vaccine (heterologous booster dose), no new
safety issues were identified.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage b8476e5276dfd76deb0a696e300e284f6b11c8983bbbda847502ad21958e105d · Zeichen 8609–8917 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148883 · Präparat HOS-099980
Omicron-adapted Comirnaty
Infants 6 months to 23 months of age - after 2 doses
In 2 groups from Study 6 (Phase 2/3, Groups 1 and 2), 604 participants 6 months to 23 months of age
who were COVID-19 vaccine-naïve received 2 doses of Comirnaty Omicron XBB.1.5 10 mcg.
Participants had a median follow-up time of 8.5 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage bef8155c0f5e5fdc0f59a9340c5e9b888edca33353bc492dee17a18a97b2314c · Zeichen 8919–9239 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148884 · Präparat HOS-099980
The most frequent adverse reactions in participants 6 months to less than 23 months of age were
decreased appetite, drowsiness, and irritability (> 20%), and tenderness at the injection site (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 212c5d2b95baffd1adbb7b8c874288f1190ce2471f5de4eb27e37ebbac83c22f · Zeichen 9241–9440 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148885 · Präparat HOS-099980
Infants 6 months to 23 months of age - after at least 3 doses
In 3 groups from Study 6 (Phase 1), 95 participants 6 months to 23 months of age received at least
1 dose of Comirnaty Original/Omi BA.4/BA.5 at 3 mcg (n=33), 6 mcg (n=29), or 10 mcg (n=33),
administered at 0, 3, and 11 weeks. Participants had a median follow-up time of 13 monthsafter the
third dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage f2f4926219fd83fc0eda99067c66e6952fb72ddab45c750f5d34527970a14cc3 · Zeichen 9442–9805 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148886 · Präparat HOS-099980
The most frequent adverse reactions in participants who received the 10 mcg 3-dose series were
irritability (> 60%), drowsiness (> 50%), tenderness at the injection site and decreased appetite
(> 30%), redness (> 20%), and swelling (> 10%).
Children 2 to 4 years of age – after a single dose
In 2 groups from Study 6 (Phase 2/3, Groups 4 and 5), 688 participants 2 to 4 years of age who were
COVID-19 vaccine-naïve, received a single dose of Comirnaty Omicron XBB.1.5 10 mcg.
Participants had a median follow-up time of 6.3 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 6be8685ce638a91ed596d34baf85aff31f0f265cddac2ba03470ab3d3a49128d · Zeichen 9807–10338 im Abschnitt
Nebenwirkungen · Comirnaty
Comirnaty JN.1 30 micrograms/dose dispersion for injection Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty JN.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 9
HOS-148887 · Präparat HOS-099980
The most frequent adverse reactions in participants 2 to 4 years of age were pain at the injection site
and fatigue (> 20%), and headache (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 130ec4703cb38ac0f9cb0fc414b84f04ec6478cd4fc48d398547776a2fa01be7 · Zeichen 10340–10486 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.